Modulation of A2a receptor antagonist on D2 receptor internalization and ERK phosphorylation

Acta Pharmacologica Sinica

Volumn 34, Issue 10, 2013, Pages 1292-1300

  Huang, Li ^a   Wu, Dong Dong ^a   Zhang, Lei ^a   Feng, Lin Yin ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

arrestin; A2a receptor; D2 receptor; ERK; Parkinson's disease; Receptor heterodimerization; Receptor internalization; Src kinase; Striatum; ZM241385

Indexed keywords

BETA ARRESTIN; MITOGEN ACTIVATED PROTEIN KINASE; QUINPIROLE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; DOPAMINE 2 RECEPTOR; PROTEIN TYROSINE KINASE; RETINA S ANTIGEN; TRIAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BIOTINYLATION; CELL CULTURE; CELL LYSATE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORPUS STRIATUM; DIMERIZATION; ENZYME PHOSPHORYLATION; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; NERVE CELL; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; RAT; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; METABOLISM; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; SPRAGUE DAWLEY RAT; CELL STRAIN HEK293; DRUG EFFECT;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; ARRESTINS; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER TECHNIQUES; CELLS, CULTURED; CORPUS STRIATUM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; NEURONS; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; SRC-FAMILY KINASES; TRIAZINES; TRIAZOLES;

EID: 84887393403     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.87     Document Type: Article

References (28)

1. Stoof JC, Kebabian JW. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 1981; 294: 366-8. (Pubitemid 12202858)
2. 2 receptor. Mol Endocrinol 2004; 18: 640-52. (Pubitemid 38328208)
3. 2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Mol Pharmacol 1991; 39: 364-9.
4. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 2004; 24: 165-205. (Pubitemid 39332216)
5. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 182-217.
6. 2 dopamine receptor internalization. Synapse 2009; 63: 621-4.
7. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-92. (Pubitemid 28477681)
8. 2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 2003; 278: 46741-9. (Pubitemid 37452253)
9. 2 receptors. J Biol Chem 2002; 277: 18091-7. (Pubitemid 34967623)
10. 2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des 2008; 14: 1468-74. (Pubitemid 351997812)
11. 2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008; 63: 295-302. (Pubitemid 351499859)
12. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003; 61: 297-303. (Pubitemid 36975955)
13. 2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging 2005; 22: 471-82. (Pubitemid 41003061)
14. Hurley MJ, Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther 2006; 111: 715-28. (Pubitemid 44118432)
15. 1 receptor-mediated transactivation of the EGF receptor produces a neuroprotective effect on cortical neurons in vitro. Acta Pharmacol Sin 2009; 30: 889-98.
16. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999; 399: 697-700. (Pubitemid 29289066)
17. Liu Y, Tao YM, Woo RS, Xiong WC, Mei L. Stimulated ErbB4 internalization is necessary for neuregulin signaling in neurons. Biochem Biophys Res Commun 2007; 354: 505-10. (Pubitemid 46161352)
18. Cao Y, Sun WC, Jin L, Xie KQ, Zhu XZ. Activation of adenosine A1 receptor modulates dopamine D1 receptor activity in stably cotransfected human embryonic kidney 293 cells. Eur J Pharmacol 2006; 548: 29-35. (Pubitemid 44397009)
19. Krupnick JG, Santini F, Gagnon AW, Keen JH, Benovic JL. Modulation of the arrestin-clathrin interaction in cells. Characterization of beta-arrestin dominant-negative mutants. J Biol Chem 1997; 272: 32507-12. (Pubitemid 28011936)
20. 2 receptor-mediated ERK activation. Biochem Biophys Res Commun 2008; 377: 705-9.
21. Rozenfeld R, Devi LA. Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by - opioid receptor heterodimers. FASEB J 2007; 21: 2455-65. (Pubitemid 47230675)
22. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. β-Arrestins and cell signaling. Annu Rev Physiol 2007; 69: 483-510.
23. Ceresa BP, Schmid SL. Regulation of signal transduction by endocytosis. Curr Opin Cell Biol 2000; 12: 204-10. (Pubitemid 30142567)
24. Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 2007; 28: 416-22.
25. 2 agonist-induced beta-arrestin2 recruitment. J Mol Biol 2011; 406: 687-99.
26. 2A adenosine receptor bound to an antagonist. Science 2008; 322: 1211-7.
27. 2A receptor structures reveal common features of GPCR activation. Nature 2011; 474: 521-5.
28. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 2010; 25: 1437-43.